Sigma Planning Corp Cue Biopharma, Inc. Transaction History

Sigma Planning Corp

$3.18 Billion
Q2 2025

A detailed history of Sigma Planning Corp transactions in Cue Biopharma, Inc. stock. As of the latest transaction made, Sigma Planning Corp holds 55,500 shares of CUE stock, worth $43,845. This represents 0.0% of its overall portfolio holdings.

Number of Shares

55,500

Previous 326,260 82.99%

Holding current value

$43,845

Previous $296,000 87.5%

% of portfolio

0.0%

Previous 0.01%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 05, 2025	SELL	$0.58 - $0.86 $157,040 - $232,853	-270,760 Reduced 82.99%	55,500 $37,000
Q1 2025 May 01, 2025	SELL	$0.91 - $1.75 $110,032 - $211,601	-120,915 Reduced 27.04%	326,260 $296,000
Q4 2024 Feb 03, 2025	BUY	$0.71 - $1.88 $32,553 - $86,198	45,850 Added 11.42%	447,175 $460,000
Q3 2024 Nov 01, 2024	BUY	$0.45 - $1.08 $60,882 - $146,118	135,295 Added 50.86%	401,325 $305,000
Q2 2024 Aug 05, 2024	BUY	$1.24 - $2.18 $12,431 - $21,854	10,025 Added 3.92%	266,030 $329,000
Q1 2024 May 01, 2024	BUY	$1.77 - $3.09 $260,420 - $454,631	147,130 Added 135.14%	256,005 $483,000
Q4 2023 Feb 01, 2024	SELL	$1.72 - $3.1 $233,627 - $421,073	-135,830 Reduced 55.51%	108,875 $287,000
Q3 2023 Nov 06, 2023	BUY	$2.23 - $4.69 $43,273 - $91,009	19,405 Added 8.61%	244,705 $562,000
Q2 2023 Aug 01, 2023	BUY	$3.11 - $4.91 $13,718 - $21,658	4,411 Added 2.0%	225,300 $822,000
Q1 2023 May 05, 2023	BUY	$2.41 - $3.74 $67,853 - $105,299	28,155 Added 14.61%	220,889 $788,000
Q4 2022 Jan 24, 2023	BUY	$2.39 - $3.95 $10,300 - $17,024	4,310 Added 2.29%	192,734 $0
Q3 2022 Nov 10, 2022	BUY	$2.23 - $3.37 $47,539 - $71,841	21,318 Added 12.76%	188,424 $420,000
Q2 2022 Aug 11, 2022	BUY	$2.49 - $5.92 $93,071 - $221,277	37,378 Added 28.81%	167,106 $416,000
Q1 2022 Apr 20, 2022	BUY	$4.41 - $12.28 $193,312 - $538,293	43,835 Added 51.03%	129,728 $633,000
Q4 2021 Feb 02, 2022	BUY	$10.86 - $17.85 $17,919 - $29,452	1,650 Added 1.96%	85,893 $971,000
Q3 2021 Oct 28, 2021	BUY	$10.06 - $15.3 $25,572 - $38,892	2,542 Added 3.11%	84,243 $1.23 Million
Q2 2021 Aug 13, 2021	BUY	$10.9 - $14.53 $93,881 - $125,146	8,613 Added 11.78%	81,701 $952,000
Q1 2021 May 06, 2021	BUY	$11.2 - $16.09 $16,934 - $24,328	1,512 Added 2.11%	73,088 $892,000
Q4 2020 Feb 09, 2021	BUY	$11.12 - $16.4 $130,693 - $192,749	11,753 Added 19.65%	71,576 $895,000
Q3 2020 Nov 03, 2020	BUY	$15.05 - $23.54 $101,497 - $158,753	6,744 Added 12.71%	59,823 $900,000
Q2 2020 Jul 31, 2020	SELL	$12.7 - $30.73 $167,208 - $404,591	-13,166 Reduced 19.87%	53,079 $1.3 Million
Q1 2020 May 01, 2020	BUY	$9.85 - $22.27 $8,717 - $19,708	885 Added 1.35%	66,245 $940,000
Q4 2019 Feb 03, 2020	BUY	$7.06 - $17.47 $36,359 - $89,970	5,150 Added 8.55%	65,360 $1.04 Million
Q3 2019 Nov 01, 2019	BUY	$6.78 - $9.28 $84,105 - $115,118	12,405 Added 25.95%	60,210 $508,000
Q2 2019 Aug 01, 2019	BUY	$7.18 - $9.65 $40,969 - $55,062	5,706 Added 13.55%	47,805 $430,000
Q1 2019 May 01, 2019	BUY	$4.7 - $9.29 $197,865 - $391,099	42,099 New	42,099 $325,000

Others Institutions Holding CUE

# of Institutions

Shares Held

17.7M

Call Options Held

Put Options Held

View Full List

About Cue Biopharma, Inc.

Ticker CUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,381,700
Market Cap $28M
Description
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...

More about CUE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Sigma Planning Corp, based on Form 13F filings with the SEC.

News

Stay updated on Sigma Planning Corp with notifications on news.

Account

Sigma Planning Corp Cue Biopharma, Inc. Transaction History